Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trialYolanda Barbáchano, Alicia Okines, Andrew Wotherspoon et al.|The Lancet Oncology|2013Cited by 728
Impact on quality of life (QoL) of FEC-T compared with FEC or E-CMF: UK Taxotere as Adjuvant Chemotherapy Trial (TACT) 2-year follow-upPenelope Hopwood, David Cameron, Antonia Ridolfi et al.|Journal of Clinical Oncology|2008Cited by 3